Alnylam Pharmaceuticals, Inc.
ALNY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001178670
No open-market purchases or sales by Alnylam Pharmaceuticals, Inc. insiders were filed in the last 90 days; 794 institutions reported holding it in 13F filings for Q2 2026, worth $40.1B in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Alnylam Pharmaceuticals, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 823
- +178 vs. Q2 2025
- Shares held
- 129.9M
- −193.8K (−0.1%) vs. Q2 2025
- Total value
- $59.2B
- +$16.8B (+39.6%) vs. Q2 2025
- New holders
- 225
- 283 more added
- Sold out
- 47
- 223 more reduced
8 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ALNY on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 794 | $40.1B |
| Q1 2026 | 793 | $43.4B |
| Q4 2025 | 852 | $52.7B |
| Q3 2025 | 823 | $59.2B |
| Q2 2025 | 653 | $43.1B |
| Q1 2025 | 625 | $34.8B |
| Q4 2024 | 594 | $30.1B |
| Q3 2024 | 569 | $34.1B |
| Q2 2024 | 525 | $29.1B |
| Q1 2024 | 499 | $17.2B |
| Q4 2023 | 501 | $22.4B |
| Q3 2023 | 454 | $20.9B |
| Q2 2023 | 477 | $22.5B |
| Q1 2023 | 478 | $24.0B |
| Q4 2022 | 489 | $28.4B |
| Q3 2022 | 497 | $26.7B |
| Q2 2022 | 424 | $16.6B |
| Q1 2022 | 443 | $18.6B |
| Q4 2021 | 435 | $19.0B |
| Q3 2021 | 407 | $21.1B |
| Q2 2021 | 401 | $19.0B |
| Q1 2021 | 391 | $15.4B |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Alnylam Pharmaceuticals, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Northern Trust Corp | 833,151 | $379.9M | 0.05% | +1,374+0.2% | Added |
| Legal & General Group Plc | 887,780 | $404.8M | 0.09% | +15,009+1.7% | Added |
| Two Sigma Advisers, LP | 892,500 | $407.0M | 0.81% | +626,400+235.4% | Added |
| Jane Street Group, LLC | 958,750 | $437.2M | 0.51% | +935,894+4,094.7% | Added |
| Arrowstreet Capital, Limited Partnership | 1,355,609 | $618.2M | 0.39% | +1,185,909+698.8% | Added |
| Regeneron Pharmaceuticals, Inc. | 1,392,303 | $634.9M | 90.64% | −3,052,142−68.7% | Reduced |
| Invesco Ltd. | 1,481,842 | $675.7M | 0.11% | +140,148+10.4% | Added |
| Bank of America Corp | 1,498,491 | $683.3M | 0.05% | +241,163+19.2% | Added |
| American Century Companies Inc | 1,641,441 | $748.5M | 0.38% | −152,405−8.5% | Reduced |
| Price T Rowe Associates Inc | 1,800,294 | $820.9M | 0.09% | −1,344,712−42.8% | Reduced |
| Wellington Management Group LLP | 1,826,321 | $832.8M | 0.15% | −249,431−12.0% | Reduced |
| Orbis Allan Gray Ltd | 1,950,962 | $889.6M | 3.82% | −170,450−8.0% | Reduced |
| T. Rowe Price Investment Management, Inc. | 2,173,984 | $991.3M | 0.61% | −2,107,295−49.2% | Reduced |
| Dodge & Cox | 2,321,230 | $1.06B | 0.57% | −875,866−27.4% | Reduced |
| Geode Capital Management, LLC | 2,499,242 | $1.14B | 0.07% | +100,472+4.2% | Added |
| Baillie Gifford & Co | 2,789,356 | $1.27B | 0.94% | −242,535−8.0% | Reduced |
| State Street Corp | 3,081,475 | $1.41B | 0.05% | −91,630−2.9% | Reduced |
| JPMorgan Chase & Co | 4,543,770 | $2.07B | 0.13% | +2,481,762+120.4% | Added |
| Capital Research Global Investors | 7,222,840 | $3.29B | 0.62% | +31,184+0.4% | Added |
| BlackRock, Inc. | 9,903,601 | $4.52B | 0.08% | −76,562−0.8% | Reduced |
| Vanguard Group Inc | 13,565,452 | $6.19B | 0.09% | +268,313+2.0% | Added |
| Capital World Investors | 16,434,253 | $7.49B | 1.02% | −370,754−2.2% | Reduced |
| FMR LLC | 16,767,625 | $7.65B | 0.40% | +961,104+6.1% | Added |
| Tri Locum Partners LP | 0 | $0 | 0.00% | −89,525−100.0% | Sold out |
| Adage Capital Partners GP, L.L.C. | 0 | $0 | 0.00% | −84,390−100.0% | Sold out |
| AXA S.A. | 0 | $0 | 0.00% | −82,480−100.0% | Sold out |
| PFM Health Sciences, LP | 0 | $0 | 0.00% | −72,220−100.0% | Sold out |
| Cercano Management LLC | 0 | $0 | 0.00% | −56,953−100.0% | Sold out |
| Ikarian Capital, LLC | 0 | $0 | 0.00% | −56,594−100.0% | Sold out |
| Iron Triangle Partners LP | 0 | $0 | 0.00% | −29,339−100.0% | Sold out |
| Cinctive Capital Management LP | 0 | $0 | 0.00% | −22,868−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −19,213−100.0% | Sold out |
| First Turn Management, LLC | 0 | $0 | 0.00% | −17,879−100.0% | Sold out |
| Mirae Asset Securities (USA) Inc. | 0 | $0 | 0.00% | −13,034−100.0% | Sold out |
| Readystate Asset Management LP | 0 | $0 | 0.00% | −11,601−100.0% | Sold out |
| Portman Square Capital LLP | 0 | $0 | 0.00% | −6,967−100.0% | Sold out |
| Sivik Global Healthcare LLC | 0 | $0 | 0.00% | −6,500−100.0% | Sold out |
| Hussman Strategic Advisors, Inc. | 0 | $0 | 0.00% | −6,300−100.0% | Sold out |
| V-Square Quantitative Management LLC | 0 | $0 | 0.00% | −1,692−100.0% | Sold out |
| Bryn Mawr Trust Co | 0 | $0 | 0.00% | −1,686−100.0% | Sold out |
| Ewing Morris & Co. Investment Partners Ltd. | 0 | $0 | 0.00% | −1,440−100.0% | Sold out |
| Banco Santander, S.A. | 0 | $0 | 0.00% | −1,245−100.0% | Sold out |
| Quantitative Investment Management, LLC | 0 | $0 | 0.00% | −1,238−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −1,134−100.0% | Sold out |
| Jupiter Asset Management Ltd | 0 | $0 | 0.00% | −974−100.0% | Sold out |
| Eqis Capital Management, Inc. | 0 | $0 | 0.00% | −934−100.0% | Sold out |
| Nebula Research & Development LLC | 0 | $0 | 0.00% | −900−100.0% | Sold out |
| ICONIQ Capital, LLC | 0 | $0 | 0.00% | −806−100.0% | Sold out |
| Strategic Financial Concepts, LLC | 0 | $0 | 0.00% | −750−100.0% | Sold out |
| GTS Securities LLC | 0 | $0 | 0.00% | −747−100.0% | Sold out |
| Flow Traders U.S. LLC | 0 | $0 | 0.00% | −740−100.0% | Sold out |
| Volterra Technologies LP | 0 | $0 | 0.00% | −490−100.0% | Sold out |
| Skopos Labs, Inc. | 0 | $0 | 0.00% | −481−100.0% | Sold out |
| Catalyst Capital Advisors LLC | 0 | $0 | 0.00% | −453−100.0% | Sold out |
| Tobam | 0 | $0 | 0.00% | −353−100.0% | Sold out |
| Geneos Wealth Management Inc. | 0 | $0 | 0.00% | −238−100.0% | Sold out |
| New York State Teachers Retirement System | 0 | $0 | 0.00% | −191−100.0% | Sold out |
| Mount Yale Investment Advisors, LLC | 0 | $0 | 0.00% | −113−100.0% | Sold out |
| Sierra Ocean, LLC | 0 | $0 | 0.00% | −68−100.0% | Sold out |
| Whipplewood Advisors, LLC | 0 | $0 | 0.00% | −42−100.0% | Sold out |
| MB, Levis & Associates, LLC | 0 | $0 | 0.00% | −35−100.0% | Sold out |
| Twin Peaks Wealth Advisors, LLC | 0 | $0 | 0.00% | −15−100.0% | Sold out |
| Riggs Asset Managment Co. Inc. | 0 | $0 | 0.00% | −17−100.0% | Sold out |
| Curio Wealth, LLC | 0 | $0 | 0.00% | −10−100.0% | Sold out |
| HHM Wealth Advisors, LLC | 0 | $0 | 0.00% | −7−100.0% | Sold out |
| Trifecta Capital Advisors, LLC | 0 | $0 | 0.00% | −7−100.0% | Sold out |
| WealthTrak Capital Management LLC | 0 | $0 | 0.00% | −6−100.0% | Sold out |
| Garde Capital, Inc. | 0 | $0 | 0.00% | −5−100.0% | Sold out |
| Stephens Consulting, LLC | 0 | $0 | 0.00% | −5−100.0% | Sold out |
| Richardson Financial Services Inc. | 0 | $0 | 0.00% | −5−100.0% | Sold out |
| Norges Bank | – | – | – | – | Not filed |
| CIBC World Markets Corp | – | – | – | – | Not filed |
| E Fund Management Co., Ltd. | – | – | – | – | Not filed |
| Avantax Advisory Services, Inc. | – | – | – | – | Not filed |
| EP Wealth Advisors, LLC | – | – | – | – | Not filed |
| First Horizon Advisors, Inc. | – | – | – | – | Not filed |
| Semmax Financial Advisors Inc. | – | – | – | – | Not filed |
| Parkworth Wealth Management, Inc. | – | – | – | – | Not filed |